Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Ovid Therapeutics (NASDAQ: OVID) will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET. The presentation aims to discuss the company’s commitment to developing transformative treatments for rare neurological diseases. Live access to the audio webcast will be available on the company’s website, with an archived replay post-event. Ovid’s key investigational medicine, OV101, is under development for Angelman and Fragile X syndromes, while OV935 is being developed in collaboration with Takeda for rare developmental and epileptic encephalopathies.
- None.
- None.
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m. ET.
A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit www.ovidrx.com.
Contacts
Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com
Or
Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006
Media:
Katie Engleman
1AB
katie@1abmedia.com
FAQ
When is Ovid Therapeutics presenting at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference?
How can I access the Ovid Therapeutics conference presentation?
What is the focus of Ovid Therapeutics' presentation at the conference?
What are the key investigational medicines of Ovid Therapeutics?
Is there a replay available for the Ovid Therapeutics conference presentation?
